Lantern Pharma is trading 6.2% lower at $0.57, with no specific catalyst established.
- No company-specific announcement explaining the November 4 move appears in the company’s published 2026 press-release listings.
- The decline runs counter to gains in the broader market and biotech sector; those trends do not explain the drop.
- Shares had also fallen in recent sessions, but that alone does not identify the cause.